Clinical trial · Interventional
Image-Guided Gynecologic Brachytherapy
A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma of the Vulva | Vulvar Carcinoma | ALIAS | 0.90 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Uterine Cancer | Malignant Uterine Neoplasm | ALIAS | 0.90 |
| Vaginal Cancer | Malignant Vaginal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3'-Deoxy-3'-18f-Fluorothymidine | Drug | — | UNRESOLVED |
| Image-guided brachytherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Image-Guided Brachytherapy
- description
- Image-guided brachytherapy
- interventionNames
- Procedure: Image-guided brachytherapy
- Drug: 3'-Deoxy-3'-18f-Fluorothymidine
Primary outcomes (1)
- measure
- Mean Doses Given
- timeFrame
- Measured while on treatment, up to 2 months.
- description
- Doses given to the tumor, rectum, and sigmoid obtained after AMIGO-guided placement.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed carcinoma of the cervix (Stage I-IVA), carcinoma of the uterus (Stage IIIB), carcinoma of the vagina (Stage I-IVA), or carcinoma of the vulva (stage I-IVA) * Life expectancy \> 6 months * MRI of the pelvis and/or PET-CT within 4 months prior to entering study Exclusion Criteria: * Uncontrolled intercurrent illness * Pacemaker, brain aneurysm clip, inner ear implant, neurostimulator, or metal fragments in the eye
References
Publications (0)
Data not yet available